The company is offering BetaVia in two new water-dispersible versions.
Kemin Industries (Des Moines, IA) has introduced water-dispersible versions of its BetaVia immune health ingredients. BetaVia is a beta-glucan derived from algae (Euglena gracilis). Now, there are two new water-dispersible versions of the company’s BetaVia Pure and BetaVia Complete ingredients.
BetaVia Complete is the company’s whole-algae fermentate ingredient containing more than 50% algae-sourced beta-glucans plus protein and essential vitamins, minerals, and amino acids. Meanwhile, BetaVia Pure is “the highest purity of beta-glucan currently available on the market, with greater than 95% beta 1,3 glucans,” the company’s press release says.
The new BetaVia Pure WD and BetaVia Complete WD ingredients offer formulators numerous benefits. “Since beta 1,3 glucans are naturally insoluble, formulating them for drink mixes, sachets, or other applications that require water dispersion can be challenging. By addressing these obstacles, the new water-dispersible BetaVia product form delivers improved results.”
In the press release, Kemin Human Nutrition and Health’s global product manager, Chris Sadewasser, said, “The rising interest in nutritious, functional, and sustainable ingredients for food and dietary supplements makes algae a more attractive option.” BetaVia ingredients are suited for tablets and capsules; beverages, syrups, and liquids; gummies and chews; powders and stick packs; and softgels.
HHS announces restructuring plans to consolidate divisions and downsize workforce
Published: March 27th 2025 | Updated: March 27th 2025According to the announcement, the restructuring will save taxpayers $1.8 billion per year by reducing the workforce by 10,000 full-time employees and consolidating the department’s 28 divisions into 15 new divisions.
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.